drugset
drugset / Trial / NCT03260166

Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus

NCT03260166 ↗

Phase 2 Unknown 40 enrolled Second Xiangya Hospital of Central South University Hunan Provincial Natural Science Foundation of China · collabNational Key Clinical Specialty Construction Project of China · collabNational Natural Science Foundation of China · collab
NaSingle-groupOpen-labelTreatment

Summary

This clinical study will test the efficacy and safety of nicotinamide for lupus-associated skin lesions refractory to the treatment of hydroxychloroquine plus low-dose corticosteroids in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE).

Timeline

Start
2017-08-31
Primary completion
2020-01-01
Completion
2021-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotinamide Other / unclassified 500 mg Oral

Indications

cutaneous lupus erythematosus systemic lupus erythematosus